ABSTRACT. Breast cancer, which derives from the epithelium of the mammary glands, is one of the most common cancers diagnosed in women globally. To date, the authors of many studies have reported that the deregulation of microRNAs (miRNAs) plays a crucial role in the occurrence, development, and metastasis of tumors. Here, we discovered that miR-660-5p was upregulated in the breast cancer cell lines MCF7 and MDA-MB-231 compared with that in the normal control cell line CCD-1095Sk. We then inhibited the expression of miR-660-5p to investigate its biological function in cancer development, progression, and metastasis. We determined the changes in the levels of expression of transcription factor CP2 (TFCP2) and CDKN1A to further clarify the specific mechanism involved. The results showed that downregulation of miR-660-5p significantly suppressed the proliferation, migration, and invasion of MCF7 breast cancer cell. Moreover, inhibition of miR- 660-5p promoted cell cycle G1 arrest and reduced apoptosis in breast cancer cells. The specific mechanism studies confirmed that TFCP2 was a direct downstream target of miR-660-5p. Aberrant expression of miR-660-5p repressed TFCP2 expression, whereas inhibition of miR-660-5p decreased TFCP2 protein expression, which is a vital factor in the downstream signaling pathway. In conclusion, miR-660-5p can regulate the proliferation, migration, and invasion of human breast cancer cells, and is a novel potential therapeutic target for the clinical treatment of breast cancer.
660-5p promoted cell cycle G1 arrest and reduced apoptosis in breast cancer cells. The specific mechanism studies confirmed that TFCP2 was a direct downstream target of miR-660-5p. Aberrant expression of miR-660-5p repressed TFCP2 expression, whereas inhibition of miR-660-5p decreased TFCP2 protein expression, which is a vital factor in the downstream signaling pathway. In conclusion, miR-660-5p can regulate the proliferation, migration, and invasion of human breast cancer cells, and is a novel potential therapeutic target for the clinical treatment of breast cancer.
INTRODUCTION
Breast cancer is one of the most common cancers diagnosed in women globally, and is the second leading cause of cancer-related death among women, after lung cancer (Siegel et al., 2013; DeSantis et al., 2014) . Furthermore, metastasis is the most common cause of mortality in patients with breast cancer. Breast cancer is a heterogenous disease characterized by diverse molecular subtypes, various clinical behaviors, and distinct molecular features (Sørlie et al., 2001; Goldhirsch et al., 2011) . Previous studies have disclosed that the development of malignant tumors in the breasts is a complex multistep process that involves numerous genetic alterations, giving rise to the deregulation of significant complicated pathways in cellular processes, such as migration, proliferation, apoptosis, and invasion (Porter et al., 2001; Bourguignon et al., 2003; Umetani et al., 2006) . MicroRNAs (miRNAs) are non-coding RNA molecules that are approximately 18-25 nucleotides long. They modulate the expression of target genes and play an essential role in the biological and pathological processes of diseases (Friedman et al., 2009) . The use of miRNAs as potential biomarkers for diagnosis and prognosis and as therapeutic agents in various cancers has risen in recent years (Liu et al., 2012) . Several studies have indicated that miRNAs, such as miR-181a and miR-34a, serve as oncogenes or tumor suppressors; they affect breast cancer development and metastasis by regulating mRNA targets (He et al., 2005; Lee and Dutta, 2007; Li et al., 2013; Taylor et al., 2013) .
Transcription factor CP2 (TFCP2), also known as LSF and LBP-1c, was first identified as a late transcriptional activator of the simian virus 40 (SV40) promoter in HeLa cells (Kim et al., 1987) . Subsequently, it was found that TFCP2 is expressed in all mammalian cell types as a ubiquitous transcription factor, and plays a role in cell cycle progression and cell survival, as well as in cell lineage-specific functions (Xu et al., 2015) . Previous studies have also shown that TFCP2 plays a critical role in malignant cancer progression from the G1 phase to the S phase of the cell cycle (Saxena et al., 2010) . TFCP2 functions as an oncogene in hepatocellular carcinomas, and an increased expression level of TFCP2 promotes malignant progression (Saxena et al., 2010) . Goto et al. (2016) found an opposite role of TFCP2 in melanoma, whereby increased TFCP2 expression levels suppressed both the anchorage-dependent and -independent growth of melanoma cells. However, the functions and the specific molecular mechanism of action of TFCP2 in breast cancer remain obscure.
Previous studies have revealed that miRNA-660-5p (miR-660-5p) is upregulated in patients with breast cancer (Krishnan et al., 2015) . Several databases, such as TARGETSCAN, MIRDB, and MICRORNA.ORG, have shown that TFCP2 is a potential target of miR-660-5p. In the present study, we investigated the expression of miR-660-5p in two breast cancer cell lines and a normal cell line to confirm its upregulation in breast cancer cells. We then inhibited the expression of miR-660-5p to investigate its biological function in cancer development and progression. The changes in the levels of expression of TFCP2 and CDKN1A were determined to further clarify the specific mechanism of miR-660-5p.
MATERIAL AND METHODS

Cell lines and cell culture
The human breast cancer cell lines MCF7 and MDA-MB-231, and the normal human breast fibroblast cell line CCD-1095Sk were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The human embryonic kidney cell line HEK293 was also from ATCC. MDA-MB-231 cells were cultured in L15 medium, and the MCF7, CCD1095Sk, and HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS).
RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) analysis
The total RNAs of the various cell lines were extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer instructions. The resulting RNA molecules were reverse-transcribed using a specific miRNA primer (Hsa-miR-660-5p; Funeng Biotechnology Co., Ltd., Guangzhou, China) for miRNA analysis, and were then subjected to RT-PCR, following the manufacturer protocols for the miScript SYBR Green PCR kit and the miScript Reverse Transcription kit (Funeng Biotechnology Co., Ltd., Guangzhou, China).
Cell transfection
The miR-660-5p inhibitor and the negative control miRNA inhibitor were synthesized by Guangzhou Ruibo Biotechnology (Guangzhou, China). Either the miR-660-5p inhibitor or the negative control miRNA was transfected into the MCF7 cells using Lipofectamine 2000 transfection reagent, according to the manufacturer protocol (Invitrogen). MCF7 cells transfected with only Lipofectamine 2000 transfection reagent (Invitrogen) were used as a MOCK group. Three groups of transfected MCF7 cells were used for further analysis and all assays were conducted with three replicates.
Cell proliferation determination
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure the cell proliferation rates in the three groups of transfected MCF7 cells. The cells were seeded onto 96-well plates at a density of 4000 cells per well. The cells were then maintained in a culture medium containing 5% FBS for 48 h. Finally, the absorbance at 490 nm was measured.
Cell cycle and cell apoptosis analysis
A propidium iodide cell cycle detection kit (Biotechnology's Beyotime Institute, Beijing, China) was used to analyze the cell cycle on a FACSCalibur flow cytometer (BD Biosciences, NY, USA). An Annexin V-phycoerythrin (PE) Apoptosis Detection kit I (BD) was used to perform the apoptosis assay, according to the manufacturer instructions. The results were also analyzed using a FACSCalibur flow cytometer.
Cell migration and invasion assays
The cells were seeded onto 35-mm dishes that had been coated with fibronectin to carry out the wound-healing migration assay. Once the cells had reached 100% confluence, a scratch (approximately 500 µm long) was created on the confluent monolayer using a sterile p200 pipette tip. The cellular debris was then removed by replacing the medium with fresh serum-free medium. During the subsequent 48-h culture of the cells, we obtained images at 0, 24, and 48 h. We used a Matrigel Transwell chamber (BD) filled with serum-free medium for the invasion assay. A total of 1 x 10 4 cells were filled into the upper chamber. Medium containing 10% FBS served as the chemoattractant in the lower chamber. After incubating the chamber at 37°C for 64 h, the cells that were adhered to the lower membrane were fixed, stained, and counted using a microscope and a counting chamber (Olympus, Tokyo, Japan).
RT-PCR analysis and western blotting
The mRNA and protein expression levels of TFCP2 and CDKN1A were determined to investigate the mechanism of action of miR-660-5p. For mRNA analysis, RNA was reverse-transcribed with Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, USA) and random primers (Promega). SYBR Premix Ex Taq II (Takara Biotechnology Co., Ltd., China) was used for RT-PCR. The PCR primers for TFCP2 were: F: 5'-TCTGGCCGACGAAGTGATTG-3'; and R: 5'-ATCAGGAGGCAAACTCGACTC-3'. The PCR primers for CDKN1A were: F: 5'-TGTCCGTCAGAACCCATG-3'; and R: 5'-59TGGGAAGGTAGAGCTTGG-3'. For western blotting, the cell cytoplasm and nucleus lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and analyzed on polyvinylidene fluoride membranes (Millipore, USA). Rabbit anti-human polyclonal TFCP2 or CDKN1A (dilution, 1:1000; Sigma-Aldrich, St. Louis, MO, USA) and monoclonal mouse anti-human β-actin (dilution, 1:5000; Sigma-Aldrich) antibodies were incubated with the blotted membranes. Secondary horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (dilution, 1:5000; Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA) was also incubated with the membranes. An Enhanced Chemiluminescence System (Pierce Biotechnology, Inc., Rockford, IL, USA) was used to analyze the protein bands. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and proliferating cell nuclear antigen (PCNA) expression levels were used as internal normalization controls.
containing the miR-660-5p target sequence (CAAGGAT) was inserted into the vector. Either an miR-660-5p mimic or a negative control miRNA was co-transfected into the HEK293 cells using Lipofectamine 2000 transfection reagent (Invitrogen), according to the manufacturer instructions. After incubation for 48 h, the cells were lysed. A Dual-Luciferase Reporter Assay kit (Promega) was used to carry out the luciferase reporter assay.
Statistical analysis
All experiments were performed in triplicate. The data were analyzed using SPSS 14 software (SPSS, Chicago, Illinois) and are expressed as the mean ± SD. Unless otherwise mentioned, two-sided Student's t-tests or one-way analysis of variance (ANOVA) were used to determine differences between groups. P < 0.05 was viewed as a significant difference.
RESULTS
Varying expression of miR-660-5p in breast cancer
To explore the significance and varying expression of miR-660-5p in breast cancer, mRNA expression arising from miR-660-5p was determined in breast cancer MDA-MB-231 and MCF7 cell lines, and in normal breast fibroblast cell line CCD-1095Sk. As shown in Figure 1 , miR-660-5p was significantly upregulated in the breast cancer cell lines, especially in the MCF-7 cell line, in comparison with the CCD-1095Sk cells. To explore the biological function of miR-660-5p in breast cancer cells, miR-660-5p inhibitor was transfected into the MCF7 cells for further investigation. 
Effects of miR-660-5p inhibitor on proliferation and the cell cycle in MCF7 cells
As shown in Figure 2 , the results of the MTT assay indicated that downregulation of miR-660-5p significantly inhibited MCF7 cell proliferation. The cell cycle results are shown in Figure 3 ; the results of the cell cycle distribution analysis by flow cytometry in the three groups of transfected MCF7 cells are shown in Figure 3A , B, and C. The G1 phase comprised 60.2% anti-miR-660-5p inhibitor-transfected cells, which was significantly higher than the percentage of control cells ( Figure 3D ). This indicates that the miR-660-5p inhibitortransfected MCF7 cells were arrested in the G1 phase. 
Downregulation of miR-660-5p induced apoptosis in MCF7 cells
Figure 4 reveals that downregulation of miR-660-5p induced apoptosis in the MCF7 cells. The apoptosis of MCF7 cells transfected with miR-660-5p inhibitor or control miRNA inhibitor was measured by flow cytometry and observed using an electron microscope ( Figure  4A and B) . The MCF7 cells transfected with miR-660-5p inhibitor had a 19.92% apoptosis rate, which was significantly higher than the cells in the control group ( Figure 4C ). The electron microscope images shown in Figure 4B confirm the results.
Inhibition of miR-660-5p reduced the migration and invasion of MCF7 cells
The results from the wound-healing migration experiment ( Figure 5) show that the mobility of the MCF7 cells was significantly reduced after transfection with miR-660-5p inhibitor ( Figure 5A) . The results of the Transwell assay show that, compared with the control cells, the inhibition of miR-660-5p markedly reduced the invasion of MCF7 cells ( Figure  5B ). These results suggest that miR-660-5p inhibition significantly reduced the migration and invasion of MCF7 cells. 
TFCP2 was the direct downstream target of miR-660-5p
The phenotypic data mentioned above indicate that the growth and migration of breast cancer cells were both reduced by the inhibition of miR-660-5p. Moreover, TARGETSCAN, MIRDB, and MICRORNA.ORG were used to predict the targets of miR-660-5p. Interestingly, our results suggest that TFCP2 is indeed a potential target of miR-660-5p ( Figure 6 ). We found that the 3'-UTR of TFCP2 mRNA contains a site that complements the seed region of miR-660-5p ( Figure 6A ). The human TFCP2 3'-UTR fragments with wild-type (WT 3'-UTR) or mutant (mutated 3'-UTR) miR-660-5p-binding sequences were cloned into the psiCHEK-2 vector ( Figure 6A ). Figure 6B shows that after miR-660-5p transfection, the relative luciferase activity of the reporter with WT 3'-UTR was significantly reduced. Moreover, this suppression was reversed by the site-directed deletion of the miR-660-5p-binding site of the 3'-UTR of TFCP2 ( Figure 6B ). The results confirm that miR-660-5p directly binds to this site.
Furthermore, we evaluated the ability of miR-660-5p to regulate TFCP2 expression in human breast cells. The expression levels of TFCP2 were determined in MCF7 cells transfected with the mimic or the inhibitor of miR-660-5p and miR-NC, as shown in Figure  6C and D. The TFCP2 mRNA and protein levels were upregulated by the knock-down of miR-660-5p in MCF7 cells compared with the miRNA control ( Figure 6C and D) . Above all, these results explicitly indicate that TFCP2 is a direct target of miR-660-5p in breast cancer cells. 
MiR-660-5p modulated the expression of CDKN1A
Because previous studies have shown that TFCP2 is a vital factor in the regulation of CDKN1A, we investigated the effect of miR-660-5p on CDKN1A in MCF7 cells. Figure 7 shows that the levels of nuclear CDKN1A mRNA ( Figure 7A ) and CDKN1A protein ( Figure  7B ) were significantly upregulated. That is, miR-660-5p promotes the proliferation, migration, and invasion of breast cells by regulating CDKN1A. 
DISCUSSION
The authors of several studies have reported that the dysregulation of miRNA is involved in tumorigenesis or tumor development, and increasing numbers of authors have suggested that miRNA is a critical factor in tumor cell proliferation, apoptosis, and metastasis. Fortunato et al. (2014) reported that miR-660-5p is downregulated in patients with lung cancer and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. In contrast, Krishnan et al. (2015) have reported that miR-660-5p is significantly upregulated in patients with breast cancer and can be considered a potential prognostic marker for breast cancer. In the present study, we found that miR-660-5p was significantly upregulated in human breast cancer MDA-MB-231 and MCF7 cell lines. Although the upregulation of miR-660-5p in breast cancer has been described before, the specific mechanism of action of miR-660-5p in breast cancer development and metastasis remains unknown. The present study provides the first evidence that the downregulation of miR-660-5p in breast cancer MCF7 cells significantly inhibits cell proliferation, migration, and invasion, and induces cell cycle arrest in phase G1 and cell apoptosis. Our results indicate that miR-660-5p may be a novel potential oncogene that plays a vital role in the development and metastasis of breast cancer.
As reported, the biological function of miRNAs is to regulate target genes by directly inactivating mRNA or inhibiting protein synthesis (Chekulaeva and Filipowicz, 2009 ). When we investigated the molecular mechanism of action of miR-660-5p, we found that TFCP2 has a binding site for miR-660-5p within its 3'-UTR region, as predicted. We also found that TFCP2 3'-UTR luciferase reporter activity was reduced by miR-660-5p overexpression, and this reduction was reversed by the knock-down of the miR-660-5p seed binding site. The mRNA and protein levels of TFCP2 were also suppressed by the overexpression of miR-660-5p. The inhibition of miR-660-5p increased the expression level of TFCP2 in breast cancer cells. Therefore, TFCP2 can be considered a direct target of miR-660-5p in breast cancer cells.
However, as mentioned above, TFCP2 has been identified as an oncogene or suppressor gene in various cancers. In the present study, inhibition of miR-660-5p induced the expression of TFCP2 in breast cancer cells, and miR-660-5p negatively regulated TFCP2 expression and function as a suppressor gene in breast cancer cells. Moreover, several studies have shown that CDKN1A plays a crucial role in cancer cells by modulating cell cycle arrest, cell growth, proliferation, migration inhibition, and apoptosis induction (Abbas and Dutta, 2009) . Goto et al. (2016) found that TFCP2 plays a predominant role in the regulation of CDKN1A, thereby inhibiting cell growth. In our study, CDKN1A expression was significantly upregulated when miR-660-5p was inhibited. Therefore, we conclude that downregulation of miR-660-5p suppresses tumor development and metastasis by targeting TFCP2, which further regulates CDKN1A in human breast cancer.
In conclusion, in the present study we discovered that the inhibition of miR-660-5p suppresses proliferation, migration, and invasion, and induces the apoptosis of human breast cancer cells through an miR-660-5p/TFCP2/CDKN1A signaling pathway. Although the downstream mechanism of the miR-660-5p/TFCP2/CDKN1A signaling pathway and other relevant downstream factors remain obscure, the data from our study suggest that miR-660-5p and its downstream targets may be potential therapeutic targets in human breast cancer.
